Survival, cost and added therapeutic benefit of drugs granted early access through the French temporary authorization for use program in solid tumors from 2009 to 2019-论文-万方医学网

首页> > Survival, cost and added therapeutic benefit of drugs granted early access through the French temporary authorization for use program in solid tumors from 2009 to 2019

Survival, cost and added therapeutic benefit of drugs granted early access through the French temporary authorization for use program in solid tumors from 2009 to 2019

导出原文传递

翻译打印收藏纠错

第一作者： Pham, Fiona Y-, V

作者： Pham, Fiona Y-, V ^[1] ; Jacquet, Emmanuelle ^[2] ; Taleb, Amina ^[3] ; Monard, Adrien ^[4] ; Kerouani-Lafaye, Ghania ; Turcry, Florence ; Brunel, Liora ; Grude, Francoise ; Yoldjian, Isabelle ; Sainte-Marie, Isabelle ; Boudali, Lotfi ; Blay, Jean-Yves ; Albin, Nicolas

作者单位： Oncol Hematol & Cell Therapy Dept,French Natl Agcy Safety Med & Hlth Prod ANSM ^[1] Dept Oncohematol,Ctr Hosp Univ Grenoble Alpes ^[2] Dept Oncol,Grp Hosp Sud Ile France ^[3] Dept Med Oncol,Ctr Leon Berard ^[4]

关键词 added therapeutic benefit drug costs early access program health technology assessment survival outcomes MEDICAL ONCOLOGY MAGNITUDE CLINICAL BENEFIT AMERICAN SOCIETY VALUE FRAMEWORK EUROPEAN-SOCIETY ESMO-MAGNITUDE ASCO

发布时间 2022-10-05

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

法律状态公告日	法律状态	法律状态信息

检索历史清除

Survival, cost and added therapeutic benefit of drugs granted early access through the French temporary authorization for use program in solid tumors from 2009 to 2019

相似文献

同项目论文

相关期刊

检索历史 清除

Survival, cost and added therapeutic benefit of drugs granted early access through the French temporary authorization for use program in solid tumors from 2009 to 2019

相似文献

同项目论文

相关期刊

检索历史清除